Welcome to our dedicated page for Naturl Alt Intl SEC filings (Ticker: NAII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natural Alternatives International, Inc. filings document the public-company record for a Nasdaq-listed Delaware nutritional supplement manufacturer. Recent 8-K reports describe material definitive agreements, credit-facility amendments, covenant waivers, officer employment and compensation arrangements, and principal financial-officer responsibilities.
Proxy and annual-meeting disclosures cover board elections, executive compensation votes, equity incentive plan amendments, auditor ratification, and shareholder voting results. Other filing exhibits document manufacturing agreements for customer nutritional products, revolving credit and term-loan arrangements, security interests, and governance matters affecting NAII common stock.
Natural Alternatives International reports higher sales but continued losses for the quarter and nine months ended March 31, 2026. Quarterly net sales rose to $35.5M from $28.8M, driven by 25% growth in private-label manufacturing, while patent and trademark licensing was roughly flat.
Despite 13% year-to-date sales growth to $108.0M, gross margin remained low and the company posted a nine‑month net loss of $7.2M, similar to the prior year. Operating cash flow turned negative, with $7.9M used in operations and inventories and receivables rising.
To bolster liquidity and refinance prior Wells Fargo debt, the company entered a new credit facility with Legacy Corporate Lending for an $11.0M term loan and up to $20.0M working capital line, at higher SOFR‑based rates. Management also plans to sell the corporate headquarters building to free up capital and intends to relocate functions to other properties or leased space.
Natural Alternatives International, Inc. notified the SEC that it cannot file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 on time under Rule 12b-25. The company cites ongoing efforts to close a new credit facility (a term note and working capital line of credit) and recent changes in terms from its existing lender as the principal causes of delay. The company expects to complete the credit facility closing and file the Form 10-Q within the five-day grace period provided by Rule 12b-25 and states it does not anticipate material changes to previously reported financial results.
Natural Alternatives International, Inc. reported that Chief Financial Officer Michael E. Fortin has resigned, effective May 15, 2026, to become CFO of another company with greater responsibilities and growth opportunities. While the company searches for a new CFO, President Kenneth E. Wolf, who previously served as CFO, will act as Principal Financial Officer and Principal Accounting Officer.
Natural Alternatives International, Inc. updated the employment terms of its Chief Executive Officer, Mark A. LeDoux. Effective May 1, 2026, his base salary under the U.S. agreement decreases from $475,000 per year to $255,000, along with certain reductions in benefits paid to officers.
At the same time, LeDoux entered into a new employment agreement to serve as Managing Director of the company’s wholly owned Swiss subsidiary, with a base salary of 170,000 CHF per year. The company intends his combined compensation from both roles to be approximately the same, subject to currency fluctuations.
LeDoux will continue as CEO of the U.S. entity and Chairperson of the Boards, while committing to spend at least half his time in Switzerland to help expand worldwide revenue and broaden customer opportunities through the Swiss operations.
NATURAL ALTERNATIVES INTERNATIONAL INC President, COO & Secretary Kenneth Wolf reported routine equity compensation activity. On March 6, 2026, 5,151 shares of common stock were transferred back to the company at $2.73 per share to cover his tax liability tied to the vesting of 9,166 restricted shares on March 7, 2026. He also received a grant of 15,000 shares of restricted stock under the company’s 2020 Omnibus Incentive Plan, which vest in three equal installments of 5,000 shares on March 7, 2027, March 7, 2028, and March 7, 2029. After these transactions, he directly holds 141,831 common shares.
NATURAL ALTERNATIVES INTERNATIONAL INC Chief Financial Officer Michael E. Fortin reported compensation-related stock activity. He received a grant of 12,000 shares of common stock as restricted stock under the company’s 2020 Omnibus Incentive Plan. In a related move, 4,308 shares were transferred back to the company at $2.73 per share to cover his tax liability upon vesting of 7,666 restricted shares on March 7, 2026. One-third of the new 12,000-share grant, or 4,000 shares, vests on each of March 7, 2027, March 7, 2028, and March 7, 2029. After these transactions, Fortin directly holds 58,554 common shares and indirectly holds 185 shares through an IRA.
NATURAL ALTERNATIVES INTERNATIONAL INC CEO and Chairman Mark A. LeDoux received a grant of 20,000 shares of common stock as restricted stock under the 2020 Omnibus Incentive Plan. Following this award, his direct holdings increased to 176,737 common shares.
On the same date, 3,484 shares were transferred back to the company at $2.73 per share to pay his tax liability arising from the vesting of 10,667 restricted shares on March 7, 2026, a tax-withholding disposition rather than an open-market sale. The new 20,000-share grant vests in three equal annual installments of 6,667, 6,667 and 6,666 shares on March 7, 2027, 2028 and 2029. He also reports additional indirect holdings through a family limited partnership, an IRA and custodial accounts.
Dunn Alan G reported acquisition or exercise transactions in this Form 4 filing.
Natural Alternatives International director Alan G. Dunn received a grant of 8,000 shares of Common Stock as restricted stock under the company’s 2020 Omnibus Incentive Plan. One-third vests on March 7, 2027, another third on March 7, 2028, and the final third on March 7, 2029. Following this award, he directly holds 99,211 shares.
Matherly Laura Kay reported acquisition or exercise transactions in this Form 4 filing.
NATURAL ALTERNATIVES INTERNATIONAL INC granted director Laura Kay Matherly 8,000 shares of restricted common stock as compensation under its 2020 Omnibus Incentive Plan. One-third of the award, or 2,667 shares, vests on March 7, 2027, another 2,667 shares on March 7, 2028, and the remaining 2,666 shares on March 7, 2029. After this grant, she directly holds 42,000 common shares.
Ramanathan Guru reported acquisition or exercise transactions in this Form 4 filing.
Natural Alternatives International director Guru Ramanathan received a grant of 8,000 shares of restricted common stock as equity compensation under the company’s 2020 Omnibus Incentive Plan. These shares were granted at no cash cost and increase his direct holdings to 38,000 shares.
The restricted stock vests in three equal annual installments: 2,667 shares on March 7, 2027, 2,667 shares on March 7, 2028, and 2,666 shares on March 7, 2029. This structure is designed to vest over three years of continued board service.